Nurix Therapeutics, Inc. NRIX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -439.3%-30.4pp | -340.2%+50.4pp | -319.3%+24.0pp | -260.8%+26.7pp | -408.9%-214pp | |
| Net margin | -411.4%-42.0pp | -314.9%+39.9pp | -292.5%+21.2pp | -234.6%+30.3pp | -369.4%-190pp | |
| EBITDA margin | -427.3%-35.5pp | -329.8%+43.7pp | -308.4%+19.5pp | -250%+24.3pp | -391.8%-207pp | |
| Free cash flow margin | -378.7%-21.4pp | -313.7%+19.7pp | -288.4%— | -255.5%— | -357.3%— | |
| Returns | ||||||
| Return on equity | -61.4%+2.8pp | -49.6%+3.6pp | -65.4%-7.4pp | -50.7%+1.7pp | -64.2%+1.2pp | |
| Return on assets | -47.2%-2.3pp | -39%-1.2pp | -47.3%-4.2pp | -37.6%+0.7pp | -44.9%-2.5pp | |
| Return on invested capital | -70.2%+9.6pp | -72.2%-3.5pp | -81.8%-4.7pp | -66.2%+6.6pp | -79.8%-0.8pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | 0.2×0.0× | 0.1×-0.1× | |
| Liquidity | ||||||
| Current ratio | 6×-0.3× | 7×+0.6× | 5.4×+0.1× | 6.8×+1.2× | 6.3×+3.4× | |
| Quick ratio | 6×-0.3× | 7×+0.6× | 5.4×+0.1× | 6.8×+1.2× | 6.3×+3.4× | |
| Cash ratio | 0.8×-0.1× | 2.9×+1.7× | 1×-0.2× | 1.1×-0.3× | 0.9×+0.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×+0.1× | 0.1×0.0× | 0.2×+0.1× | 0.1×0.0× | 0.1×-0.1× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×+0.1× | 0.1×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $4.37-24.1% | $6.22-20.8% | $4.42-14.6% | $5.34-10.2% | $5.76+87.3% | |
| Valuation | ||||||
| Market capitalization | $1.64B+40.1% | $1.79B+11.4% | $714.04M-61.1% | $744.82M-35.0% | $1.17B+52.2% | |
| Enterprise value | $1.63B+45.1% | $1.6B+4.8% | $691.12M-60.8% | $711.59M-32.7% | $1.12B+49.9% | |
| Price / sales | 22.9×+2.1× | 21.3×-8.2× | 8.5×-24.0× | 8.4×-10.0× | 20.8×+11.3× | |
| Price / book | 3.4×+1.0× | 3.3×+0.3× | 1.9×-2.9× | 1.7×-1.4× | 2.4×-2.1× | |
| EV / sales | 22.7×+2.8× | 19.1×-8.9× | 8.3×-23.0× | 8.1×-8.9× | 19.9×+10.6× | |
| Free cash flow yield | -16.6%+0.6pp | -14.7%-3.4pp | -33.8%— | -30.3%— | -17.2%— | |
| Earnings yield | -18%-0.2pp | -14.8%-2.7pp | -34.3%-24.6pp | -27.8%-13.4pp | -17.8%+1.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Nurix Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Nurix Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
